NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 116 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $27,195 | -95.2% | 10,500 | -90.8% | 0.00% | -100.0% |
| Q4 2022 | $570,272 | -94.6% | 113,600 | -86.0% | 0.00% | -90.5% |
| Q3 2022 | $10,613,334 | +2.9% | 811,366 | +0.8% | 0.02% | +10.5% |
| Q2 2022 | $10,318,319 | -17.5% | 804,886 | -1.9% | 0.02% | +5.6% |
| Q1 2022 | $12,513,587 | +72.2% | 820,536 | +100.0% | 0.02% | -5.3% |
| Q4 2021 | $7,266,000 | -14.7% | 410,264 | +1.2% | 0.02% | -20.8% |
| Q3 2021 | $8,521,000 | -26.1% | 405,367 | -30.7% | 0.02% | +41.2% |
| Q2 2021 | $11,534,000 | – | 584,882 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |